Sign up to save your podcasts
Or
Share S3:E2 – Non-Small Cell Lung Cancer Morning Commute: When and Why to Skip the Chemotherapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S3:E2 – Non-Small Cell Lung Cancer Morning Commute: When and Why to Skip the Chemotherapy
Visit MorningCommutePodcast.com/NSCLC2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts discuss PD-L1 levels, do they matter, as well as choosing the best candidates for Immune checkpoint inhibitor therapy not combined with chemotherapy, and they will also touch on recognizing adverse events.
View all episodes
By @Point of Care
5
1616 ratings
Visit MorningCommutePodcast.com/NSCLC2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts discuss PD-L1 levels, do they matter, as well as choosing the best candidates for Immune checkpoint inhibitor therapy not combined with chemotherapy, and they will also touch on recognizing adverse events.